3rd Sep 2019 13:25
(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory lymphoma.
Shares in the immunology-focused biopharmaceutical firm were down 1.9% at 355.50 pence on Tuesday.
HMPL-689 is a small molecule inhibitor which targets the phosphoinsitide-3 kinase delta isoform, a family of enzymes of involved with functions such as cell growth, proliferation and intracellular trafficking, which are involved in cancer.
Lymphoma is a form of cancer which affects the lymphatic system, a network of vessels and glands in the body that is part of the immune system.
The international study is a multi-centre, open label, two stage study, which will include dose escalation and expansion, investigating the effects of HMPL-689 administered to patients orally.
The primary outcome measures are safety and tolerability, with secondary outcomes including pharmacokinetic measurements and efficacy such as the objective response rate.
Related Shares:
Hutchmed